UPDATE 1-FDA accepts Novo Nordisk's resubmitted application for insulin drug

April 7 (Reuters) - Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a clinical trial.